Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | USP32 |
| Gene Name: | USP32 |
| Protein Full Name: | Ubiquitin carboxyl-terminal hydrolase 32 |
| Alias: | Deubiquitinating enzyme 32; NY-REN-60; NY-REN-60 antigen; UB32; ubiquitin specific peptidase 32; Ubiquitin thiolesterase 32; Ubiquitin-specific processing protease 32; UBP32; USP10 |
| Mass (Da): | 181656 |
| Number AA: | 1604 |
| UniProt ID: | Q8NFA0; Q86WP5 |
| Locus ID: | 84669 |
| COSMIC ID: | USP32 |
| Gene location on chromosome: | 17q23.1-q23.2 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 20198 |
| Percent of cancer specimens with mutations: | 0.88 |
| Normal role description: | USP32 catalyzes the thiol-dependent hydrolysis of ester-, thioester-, amide-, peptide-, and isopeptide bonds formed by the C-terminal Gly of ubiquitin. The TRE2 (USP6) oncogene is derived from chimeric fusions of USP32 and TBC1D3. |
| Commentary on involvement of protein in cancer: | 2/207 breast-, and 2/145 lung tumour samples were also mutated (Sanger COSMIC) |